Population Health

After years of discussion with Steve Groft, founding head of the NIH Office of Rare Diseases, our founder, Roger Erickson, coined the concept of a "Population Health Supply Chain" or "PHSC" and developed a plan to improve Population Health by improving net interaction rates across our entire PHSC. That concept immediately defined multiple Milestone Goals for Population Health, outlined in our recently launched Interbiome Foundation.

To fund those efforts we began launch of multiple Contract drug-Manufacturing Organizations, or "CMOs" with the dual purpose of generating an adequate profit while solving neglected but critical Population Health challenges, involving timely production of Neglected* as well as Abandoned** drugs.

Our first subsidiary, Interbiome, LLC remodeled an 11,000 sqft abandoned CMO facility originally built by the HJF and WRAIR, in Rockville, MD.

Our second facility, Interbiome-II, LLC, is in the design phase, and will be built from scratch, occupying 14,000 sqft of prior lab-space, also in Rockville, MD.

Traditional estimates for adequate corporate and supply-chain management holds that ~4% of net revenue must be spent on "M&E" or Measurement and Evaluation. Clearly, 4% of the revenue of the entire PHSC is a significant sum. We can make a significant difference by diverting even a portion of that to PHSC tuning. Teamwork generates rapidly compounding returns, and organized teams can accomplish amazing things. Hence, we are currently actively recruiting collaborators to participate in the purchase and construction of multiple, similar drug manufacturing facilities, as well as related activities.





* Neglected drugs include experimental drugs for clinical trials, whose production is delayed for lack of interest from CMOs and clinical trial management groups, usually because of lower immediate, direct profits, regardless of the net delayed, distributed costs to patients, families, employers and the public. Neglected and Abandoned drugs represent one of many aggregate coordination challenges facing current populations.



** Abandoned drugs include drugs that pharmaceutical firms have, for diverse reasons, ceased making, although they were already in commercial production and are still needed by unpredictable population subsets. Such situations usually occur because more direct profits for stockholders can be attained by switching to production of drugs with a combined volume_x_margin higher than the product being abandoned. In growing populations, however, the delayed, distributed costs to patients, families, employers and the public of abandoning needed drugs, must somehow be subsidized as a marginally growing yet easily affordable social cost. Continued production of needed but abandoned drugs is a necessary-but-not-sufficient civic activitt.